References
I. Virgolini, V. Ambrosini, J.B. Bomanji, R.P. Baum, S. Fanti, M. Gabriel et al., Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging 37, 2004–2010 (2010)
S. Ezziddin, L. Adler, A. Sabet, T.D. Poppel, F. Grabellus, A. Yuce et al., Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J. Nucl. Med. 55, 1260–1266 (2014)
R. Abgral, S. Leboulleux, D. Deandreis, A. Aupérin, J. Lumbroso, C. Dromain et al., Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10 %) well-differentiated endocrine carcinoma. J. Clin. Endocrinol. Metab. 96, 665–671 (2011)
D.H. Simsek, S. Kuyumcu, C. Turkmen, Y. Sanli, F. Aykan, S. Unal et al., Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J. Nucl. Med. 55, 1811–1817 (2014)
Conflict of interest
The authors declare that there is no conflict of interest.
Human and Animal Rights and Informed Consent
For this type of study, formal consent is not required. This article does not contain any study with animals performed by any of the authors. There is informed consent by the patient included in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lapa, C., Werner, R.A. & Herrmann, K. Visualization of tumor heterogeneity in neuroendocrine tumors by positron emission tomography. Endocrine 51, 556–557 (2016). https://doi.org/10.1007/s12020-015-0661-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0661-3